Background
==========

Sequencing of mRNA transcripts using RNA-seq protocol \[[@B1]\] is becoming the reference method for detecting and quantifying genes expressed in a cell. Although RNA-seq technology is still in the early phase and it has not disclosed completely its potential, <http://encodeproject.org/ENCODE/protocols/dataStandards/ENCODE_RNAseq_Standards_V1.0.pdf>, it can be used to discover genes created by chromosomal rearrangements. Thus, this technology represents an ideal tool for the discovery of fusion genes, formed by breakage and re-joining of two different chromosomes, which are implicated in the development of cancer \[[@B2]\]. However, normal cells seem to be also characterized by *intergenic splicing*and *transgenic splicing*, namely chimera \[[@B3]\]. As shown in Figure [1](#F1){ref-type="fig"}, *intergenic splicing*refers to a splicing event between two adjacent genes in the genome, while *transgenic splicing*is an event that produces a chimera comprising exons of two genes located on different chromosomes. Chimeras on the basis of EST estimations \[[@B4],[@B5]\] and more recently by RNA-seq \[[@B6]\] were observed in normal tissues. We refer to these approaches as *ab-initio*since the authors rely on genomic data, without additional biological support, to detect fusions. The experiments reported in \[[@B6]\] indicate that at least 4-6% of genes in the genome may be involved in chimera formation, although their prevalence was found to be generally low. Moreover, targeted alignment against artificial exon-exon junctions \[[@B6]\] of single-end reads RNA-seq data, allowed the detection of a significant amount of chimeras in normal colon and brain tissues as well as in primary colon tumors. No overlap could be observed between the results obtained with EST and RNA-seq based approaches \[[@B6]\].

![**Events involved in chimeras formation**. Chimeras, not due to a genomic pathological-associated rearrangement, may originate from two separate events: *intergenic splicing*and *transgenic splicing*. An *intergenic splicing*event combines exons from two adjacent genes of the same chromosome, while a *transgenic splicing*event combines exons from two gene locate on different chromosomes.](1471-2105-14-S7-S2-1){#F1}

Recently, Frenkel-Morgenstern et al. \[[@B7]\] described a new approach to assess chimeras. We term this procedure as the *knowledge-based approach*since it is based on fusion events extracted from published data. The authors studied 7,424 putative human chimeric RNAs \[[@B8]\] and detected the expression of 172 chimeric RNAs in 16 human tissues (Illumina Body Map 2.0, GSE30611) using high throughput RNA sequencing, mass spectrometry experimental data, and functional annotations.

Fusion finder algorithms
------------------------

In the last two years many chimera-detection tools have been developed and published. To the best of our knowledge, ChimeraScan \[[@B9]\], deFuse \[[@B10]\], FusionFinder \[[@B11]\], FusionHunter \[[@B12]\], FusionMap \[[@B13]\], MapSplice \[[@B14]\], ShortFuse \[[@B15]\], TopHat-Fusion \[[@B16]\] are the most commonly used tools for chimera detection. ChimeraScan and ShortFuse were not considered here since their run did not terminate properly during the preliminary testing phase. Before describing fusion finder algorithms, we introduce the terms used in the rest of the paper.

RNA-seq experiments provide a set of short reads that can be in two forms: single-end or paired-end. In the latter case both the forward and reverse template strands of DNA fragment are sequenced. According to the identification of fusion boundary (the nucleotide coordinates defining the breakpoint of both genes involved in the fusion) it is possible to observe two contexts: read *spanning*or read *encompassing*. Encompassing reads harbor a fusion boundary and each read maps on a different gene of the fused gene couple, while in spanning reads one mate overlaps with a fusion event, while the corresponding paired-end mate matches with one of the two genes involved in the chimera.

We have categorized the fusion detection algorithms into two classes: the *fragment-based approach*and the *pseudo-reference based approach*.

In the *fragment based approach*input reads are split into fragments, which are aligned with respect to reference (whole genome or transcriptome). The mapped fragments are then used to build a list of putative chimeras that undergo through a further selection by means of various types of filters. This category includes the following tools: FusionFinder, FusionMap, MapSlice, deFuse. *Pseudo-reference based approaches*use candidate chimeras, obtained from the previous mapping phase, to generate a new pseudo reference for chimeras detection. The fusion events resulting from the latter step are further filtered to reduce false positive. TopHat-Fusion and FusionHunter are the tools included in this category.

In this paper, we focus on fusion finder algorithms for *ab-initio*processes. Between those algorithms, FusionMap has shown the best compromise between sensitivity and sensibility. Its results have been also compared with results obtained by the *knowledge-based approach*presented in Frenkel-Morgenstern\'s paper.

Results
=======

Evaluating the sensitivity of fusion-finder algorithms
------------------------------------------------------

To compare the sensitivity of fusion-finder algorithms we used a synthetic dataset provided as part of the release of the FusionMap software, and we used it as positive dataset.

This dataset encompasses a total of 50 chimeras, supported by a different coverage. In particular, the chimeras are characterized by a number of supporting paired-end reads ranging from 9 to 8852. The analysis of the positive dataset revealed that FusionFinder is the most sensitive tools. Based on the sensitivity, the tools can be ordered as FusionFinder \> TopHat-Fusion = FusionMap \> MapSplice \> deFuse \> FusionHunter as reported in Table [1](#T1){ref-type="table"}. The table also reports the number of false chimeras detected by each tool, i.e. identification of fusion genes not present in the positive synthetic set. When ranked by the false discovery rate the order changes as follows: deFuse = FusionHunter \< FusionMap \< FusionFinder \< MapSplice \< \< TopHat-Fusion. FusionMap thus appears to provide the best compromise between sensitivity and false discovery rate.

###### 

Chimera detection performances on positive dataset encompassing 50 synthetic fusion events

  Tool            Sensitivity (%)   False discovery rate
  --------------- ----------------- ----------------------
  FusionFinder    82 (41/50)        10
  FusionMap       80 (40/50)        6
  TopHat-fusion   80 (40/50)        73
  MapSplice       78 (39/50)        23
  deFuse          64 (32/50)        4
  FusionHunter    40 (20/50)        4

In parenthesis are given the number of fusions

The sensitivity of each tool is given by the number of chimeras detected by each tool divided for the total number of chimeras in the positive dataset. False discovery rate is given as the total number of chimeras detected that do not match any of the positive 50 chimeras.

We have also evaluated the number of supporting reads detected by the six fusion finders on the positive dataset (Figure [2](#F2){ref-type="fig"}). All six tools detect a number of reads that are lower than the number present in the dataset (expected reads). It is notable that deFuse detects a number of reads near to expectation for fusions supported by more than 18 reads. Also the other tools lose sensitivity in case of a low number of supporting reads, but they are also characterized by a lack of detection for fusion events supported by a high number of reads.

![**Chimeras detection in the positive dataset**. The expected number of reads (open circle) associated to each chimera in the positive dataset is shown together with the reads detected by the six different fusion finders. THF: TopHat-fusion, FM: FusionMap, FH: FusionHunter, MS: MapSplice, DF: deFuse, FF: FusionFinder.](1471-2105-14-S7-S2-2){#F2}

Evaluating the false discovery rate of fusion finder tools
----------------------------------------------------------

To better understand the detection of false fusion events we constructed a semi-synthetic paired-end dataset composed by 70 million 100 bps reads. The dataset was built using BEERS \[[@B17]\]. BEERS does not simulate quality scores, required by many fusion finder tools, thus we added scores obtained by experiments conducted in our laboratory, giving rise to two paired-end fastq datasets: lib100_1, and lib100_2, associated with two similar sets of quality scores (Figure [3](#F3){ref-type="fig"}). Different quality score sets led to the evaluation of the effect of quality score on chimera detection. Furthermore, four other datasets, two of 75 bp reads (lib75_1, lib75_2) and two of 50 bp reads (lib50_1, lib50_2), were generated from lib100_1, lib100_2 (Figure [3](#F3){ref-type="fig"}), to evaluate the effect of read size on the detection of chimera false discovery. FusionFinder, FusionHunter, FusionMap, MapSplice, deFuse, TopHat-Fusion were used to analyze the negative datasets. Table [2](#T2){ref-type="table"} lists the number of false chimeras detected, while Figure [4](#F4){ref-type="fig"} shows read length and quality score dependency for genes involved in false fusions. FusionHunter was the only tool that did not detect false chimeras in any of the negative datasets (Table [2](#T2){ref-type="table"}). FusionMap and deFuse showed a direct dependency of the number of false chimeras from the read length (Table [2](#T2){ref-type="table"}). FusionMap also showed a limited dependency of false chimera detection on the basis of quality scores associated with the reads (Figure [4](#F4){ref-type="fig"}-FM). In comparison, FusionFinder showed an inverse dependency of false chimera detection from the read length (Table [2](#T2){ref-type="table"}) and a strong dependency of false chimera detection on the basis of the read quality scores (Figure [4](#F4){ref-type="fig"}-FF). TopHat-Fusion detected the highest number of false chimeras, although its dependency with respect to read length and quality score was limited (Figure [2](#F2){ref-type="fig"}-THF). The results of MapSplice appear to be correlated to the quality scores (Figure [2](#F2){ref-type="fig"}-MS). According to the false discovery rate, tools can be ranked as: FusionHunter \< \< FusionMap \< FusionFinder \< deFuse \< \< MapSplice \< TopHat-Fusion. We also counted the number of reads associated to the false chimeras detected by only five out of six tools, since FusionHunter did not detect any false positive chimera. In the case of TopHat-fusion and MapSplice the median of the supporting reads for false positive was one read for all negative datasets (Additional file [1](#S1){ref-type="supplementary-material"}, THF2 and MS2), but some false fusions were supported by a dozen to hundreds of reads (Additional file [1](#S1){ref-type="supplementary-material"}, THF1 and MS1). A Similar scenario was found for deFuse, with a median of the supporting reads for false positive in the order of 10 reads for all negative datasets analyzed (Additional file [1](#S1){ref-type="supplementary-material"}, DF2). FusionMap and FusionFinder were also characterized by a median of 1 for false positive supporting reads (Additional file [1](#S1){ref-type="supplementary-material"}, FM2, FF2), but in the worst situation false fusions were supported by less than 20 reads for FusionMap, in the lib50 negative dataset (Additional file [1](#S1){ref-type="supplementary-material"}, FM2), and by less than 100 reads for FusionFinder (Additional file [1](#S1){ref-type="supplementary-material"}, FF2).

![**Distribution of the quality scores associated with lib100_1 and lib100_2**. The same reads generated with BEERS software were associated with two different sets of quality scores. Upper panel: quality scores associated with lib100_1. Lower panel: quality scores associated with lib100_2. The lines in the bottom of the figure indicate the subset of quality scores used for generating the 2 × 50 and 2 × 75 nts fastq files.](1471-2105-14-S7-S2-3){#F3}

###### 

False chimera detection

  Tool            Lib50_1   lib50_2   Lib75_1   Lib100_1
  --------------- --------- --------- --------- ----------
  FusionHunter    0         0         0         0
  FusionMap       342       359       1521      2225
  FusionFinder    3517      5417      750       666
  deFuse          -\*       1532      2380      2976
  MapSplice       30022     18540     -\*       \-
  TopHat-fusion   60839     60854     122885    112779

\*The analysis did not produce the results due to a software error occurring in the handling of an intermediate file.

Number of chimeras detected in datasets free of fusion events (negative datasets). Analysis is performed using different read lengths for the same negative dataset (lib100_1, lib75_1, lib50_1). In case of the 50 nts paired-end reads negative dataset reads were also analyzed considering two different sets of experimental quality scores (lib50_1, lib50_2).

![**Venn diagrams of genes detected as part of false chimera in negative datasets**. FM) FusionMap shows a direct dependency of false chimeras with respect to the read length and a limited dependency of false chimera detection on the basis of the quality scores associated with the reads. FF) FusionFinder shows an inverse dependency of false chimeras on the basis of the read length and a strong dependency of false chimera detection on the basis of the quality scores associated with the reads. THF) TopHat-Fusion detects the highest number of false chimeras. Its dependency with respect to read length is quite limited. DF) deFuse shows a direct dependency of false chimeras on the basis of the read length. MS) MapSplice shows a significant dependency of false chimera detection on the basis of the quality scores associated with the reads. FusionHunter is not shown, since it is the only tool that does not detect false chimeras in the negative datasets.](1471-2105-14-S7-S2-4){#F4}

Searching for chimeras on real dataset with FusionMap
-----------------------------------------------------

Since FusionMap provided the best compromise between false and true fusions detection, we checked its performance on a real dataset: the Body Map 2.0. We used the 50 bp paired-end dataset and we checked FusionMap results against those presented by Frenkel-Morgenstern \[[@B7]\] on the Body Map 2.0 75 bp single-end dataset. As positive controls we used a subset of the 172 fusion events reported by the authors. We checked these 172 fusion by blasting them with respect to the genome and we ensured that each chimera encompasses genomic regions with the following characteristics: i) genomic regions should not belong to the same gene, ii) each genomic region should not match on multiple chromosomes, iii) each region involved in the fusion should not match on more than two different chromosomal loci. Unexpectedly, only 22 fusion genes, reported in Table [3](#T3){ref-type="table"}, exhibit all three characteristics; these events represent the minimal set of positive chimeras, which are expected to be detected in real dataset obtained from normal tissues.

###### 

Genomic locations of genes involved in chimeras detected in Body Map 2.0 in \[[@B7]\]

  Fusion EST                  EST source            geneA          chrA    startA        endA          geneB         chrB    startB        endB
  --------------------------- --------------------- -------------- ------- ------------- ------------- ------------- ------- ------------- -------------
  BE835085                    Li paper \[[@B21]\]   MPHOSPH10      chr2    71,357,444    71,377,232    AES           ch19    3,052,908     3,062,964
  AF103493                    Li paper \[[@B21]\]   IGKJ1          chr2    89,161,398    89,161,435    IGKV1OR22-1   chr22   17,413,617    17,415,543
  ENA\|AI400677\|AI400677.1   chimerDB_ESTs         ZMYM6NB        chr1    35,447,127    35,450,948    ALB           chr4    74,269,972    74,287,129
  ENA\|AI805048\|AI805048.1   chimerDB_ESTs         FXYD3          chr19   35,606,732    35,615,228    ZFYVE19       chr15   41,099,274    41,106,767
  ENA\|AV722190\|AV722190.1   chimerDB_ESTs         PICALM         chr11   85,668,214    85,780,923    SPP1          chr4    88,896,802    88,904,563
  ENA\|AW206715\|AW206715.1   chimerDB_ESTs         RAMP2          chr17   40,913,212    40,915,059    ZNF3          chr7    99,661,653    99,679,371
  ENA\|AW316925\|AW316925.1   chimerDB_ESTs         GNB2           chr7    100,271,363   100,276,792   QSOX1         chr1    180,123,968   180,167,169
  ENA\|AW627635\|AW627635.1   chimerDB_ESTs         LOC100294406   chr2    89,148,206    89,231,927    RBM10         chrX    47,004,617    47,046,214
  ENA\|BE903629\|BE903629.1   chimerDB_ESTs         CSNK2B         chr6    31,633,657    31,637,843    RPL8          chr8    146,015,154   146,017,805
  ENA\|BG564612\|BG564612.1   chimerDB_ESTs         GSTK1          chr7    142,960,522   142,966,222   HP            chr16   72,088,508    72,094,955
  ENA\|BG978110\|BG978110.1   chimerDB_ESTs         PSMB1          chr6    170,844,204   170,862,417   GSTP1         chr11   67,351,066    67,354,124
  ENA\|BM559993\|BM559993.1   chimerDB_ESTs         HLA-E          chr6    30457183      30,461,982    PPFIBP1       chr12   27,677,045    27,848,497
  ENA\|BM827569\|BM827569.1   chimerDB_ESTs         ELOVL5         chr6    53,132,196    53,213,977    CYBA          chr16   88,709,697    88,717,457
  ENA\|BP419192\|BP419192.1   chimerDB_ESTs         FBLIM1         chr1    16,085,255    16,113,084    AKIP1         chr11   8,932,701     8,941,626
  ENA\|BQ004985\|BQ004985.1   chimerDB_ESTs         F2RL1          chr5    76,114,833    76,131,140    COL1A2        chr7    94,023,873    94,060,544
  ENA\|BQ010435\|BQ010435.1   chimerDB_ESTs         CLSTN1         chr1    9,789,079     9,884,550     LAPTM4A       chr2    20,232,411    20,251,789
  ENA\|BU684515\|BU684515.1   chimerDB_ESTs         NDUFA13        chr19   19,627,019    19,639,013    FLNA          chrX    153,576,900   153,603,006
  ENA\|CD742870\|CD742870.1   chimerDB_ESTs         HLA-G          chr6    29,794,756    29,798,899    PPP1R15A      chr19   49,375,649    49,379,319
  ENA\|CF125182\|CF125182.1   chimerDB_ESTs         PICALM         chr11   85,668,214    85,780,923    CPQ           chr8    97,657,499    98,155,722
  ENA\|DA932721\|DA932721.1   chimerDB_ESTs         CD74           chr5    149,781,200   149,792,332   SCARF1        chr17   1,537,152     1,549,041
  ENA\|T05374\|T05374.1       chimerDB_ESTs         SRPRB          chr3    133,502,877   133,540,336   SLC22A23      chr6    3,269,207     3,456,793
  EF051633                    chimerDB_ESTmRNAs     PICALM         chr11   85,668,214    85,780,923    MLLT10        chr10   21,823,101    22,032,559

The subset of 22 chimeras encompassing only two genes on different chromosomes, extracted from the 172 events validated by Frenkel-Morgenstern, using the 75 nts single-end reads RNA-seq Body Map 2.0 dataset, was used as positive control of the ability of FusionMap to detect chimers in normal tissues RNA-seq data.

The analysis performed with FusionMap detected HLA-E (liver tissue) and SSP1 (ovary tissue) as genes involved in fusions, also identified by Frenkel-Morgenstern \[[@B7]\]. However, the authors detected HLA-E:GSTP1 and RAMP2:SPP1 fusions, whereas in our analysis we detected HLA-E:BCKDHB and SPP1:ABCA10 fusions. We also found other fusions (Table [4](#T4){ref-type="table"}), that are not part of the Frenkel-Morgenstern dataset.

###### 

Chimeras detection in Body map 2.0 by FusionMap

  Tissue              \# of genes involved in chimeras in Body Map 2.0   \# of genes also detected in the negative dataset   **\# of genes also detected as chimeras in**\[[@B7]\]   **Genes in chimeras**\[[@B7]\]   Chimeras detected by FusionMap   **Chimeras in**\[[@B7]\]
  ------------------- -------------------------------------------------- --------------------------------------------------- ------------------------------------------------------- -------------------------------- -------------------------------- --------------------------
  Adipose             74                                                 7                                                   0                                                       \-                                                                
  Adrenal             60                                                 6                                                   0                                                       \-                                                                
  Brain               56                                                 10                                                  0                                                       \-                                                                
  Breast              32                                                 2                                                   0                                                       \-                                                                
  Colon               15                                                 3                                                   0                                                       \-                                                                
  Kidney              37                                                 4                                                   0                                                       \-                                                                
  Heart               18                                                 0                                                   0                                                       \-                                                                
  Liver               31                                                 2                                                   1                                                       HLA-E                            HLA-E:BCKDHB                     HLA-E:GSTP1
  Lung                46                                                 5                                                   0                                                       \-                                                                
  Lymph node          37                                                 1                                                   0                                                       \-                                                                
  Prostate            68                                                 12                                                  0                                                       \-                                                                
  Skeletal muscle     34                                                 3                                                   0                                                       \-                                                                
  White blood cells   29                                                 4                                                   0                                                       \-                                                                
  Ovary               30                                                 3                                                   1                                                       SPP1                             SPP1:ABCA10                      RAMP2:SPP1

Number of genes detected as part of chimera in Body Map 2.0 50 nts paired-end dataset. Body Map 2.0 50 nts paired-end was generated from the same donors used for the 75 nts single-end dataset used in Frenkel-Morgenstern\'s paper to validate putative fusion by means of a *knowledge-based approach*. Thus, the two datasets are technical replication of the same mRNA universe.

Table [4](#T4){ref-type="table"} also reports, for each gene involved in the detected chimeras of Body Map, the number of genes that have been falsely detected by FusionMap in the experiment of the negative datasets.

Discussion
==========

The main goal of this paper was to understand if the main fusion detection software tools, available in the literature, are able to detect chimeras in normal tissue RNA-seq data. To reach our aim, it was essential to understand the behavior of fusion detection software tools. Thus, we evaluated the sensitivity and false discovery rate for six state-of-the-art fusion-finders: FusionHunter, FusionMap, FusionFinder, MapSplice, deFuse and TopHat-fusion.

In our experiments, FusionHunter performed better than all the other tools on the basis of false discovery rate, but had the lowest sensitivity with respect to the others. The behavior of FusionHunter is consistent with two other observations: i) FusionHunter looses all the fusions, in the positive dataset, supported by less than 18 reads, and ii) the median value for false positive chimeras for all tools, excluded FusionHunter, is between 1 to 10 reads. Thus, to reduce the risk of false positive detection, weighting negatively fusions supported by a low number of reads, FusionHunter clearly suffers of a reduced sensitivity. At the same time FusionHunter implements some specific features that make it less sensitive to the discovery of false fusions supported by a high number of reads that are frequently observable in the other fusion detection tools.

Quality scores associated with the datasets affected MapSplice and FusionFinder results. On the other hand, FusionFinder was more sensitive to read length, with a reduction in the false fusion detection rate dependent on a corresponding increase in the read length. Conversely, FusionMap and deFuse performed much better with short reads: the larger the read the higher the number of false positive fusion genes. TopHat-fusion was insensitive to quality score, but it showed the highest false positive discovery rate of the tools tested. With respect to sensitivity, deFuse and FusionHunter, were found to be the least sensitive. The best compromise between sensitivity and specificity was given by FusionMap, which seemed particularly suitable for the analysis of the Illumina normal tissue Body Map 2.0 RNA-seq dataset, since its false fusion detection rate was particularly low in the analysis of negative datasets. Despite the good sensitivity of FusionMap in the test dataset, the analysis of the Body Map 2.0 paired-end reads revealed a low correlation between FusionMap fusions detected in this dataset and fusions detected in the single-end dataset by Frenkel-Morgenstern. An important point to be considered, when comparing the results obtained with the 75 bp reads single-end and the 50 bp reads paired-end Body Map 2.0 datasets, is tissue source origin. The two datasets are generated starting, for each tissue, from the same donor, therefore we expect the results to be comparable. The lack of correspondence between true positive fusions, namely the 22 fusion events validated in the Body Map 2.0 in Frenkel-Morgenstern paper and results obtained with FusionMap on the same dataset in this paper, suggests that *ab-initio*chimera detection approaches are not sensitive enough to detect fusion genes in normal tissues. However, since chimeras detected by Frenkel-Morgenstern have a quite low representation in normal tissues, it is also possible that they were not sampled in the paired-end dataset for stochastic reasons.

Conclusions
===========

This paper highlights that specificity of state of the art tools for the identification of chimeras is affected at different degrees by read length and read quality scores of the RNA-seq dataset under analysis. Thus, it is important to carefully select the software on the basis of RNA-seq data features. In the specific case of detection of chimeras in normal tissues these fusion finder tools do not seem to provide results consistent with those obtained with a *knowledge-based approach*such as those reported by Frenkel-Morgenstern \[[@B7]\].

Methods
=======

Fusion detection software
-------------------------

*MapSplice*\[[@B14]\] splits each read in a set of consecutive elements, then exon alignment is performed. MapSplice aligns any element not mapped in the previous step, using the knowledge resulting by other aligned elements. Splice junction quality is then assessed with two statistical measures: i) \"anchor significance\", given by an alignment that maximizes significance as a result of long anchors on the two sides of the splice junction, and ii) \"entropy\" calculated by the multiplicity of splice junction locations.

*FusionMap*\[[@B13]\] splits reads into smaller portions and it finds putative chimeras aligning these elements to genes annotated on genomic reference. The read alignment is based on GSPN algorithm \[[@B13]\], that provides a tolerance to mismatches of at most two bases. Seeds located at each side of an unmapped read are aligned to the reference. Chimeras are reported only if both seeds align, all chimeras having fusion boundaries distant less than 5 bp are combined and used to refine the position of junction boundary. Canonical splicing patterns are also used to refine the site of the fusion boundary, and false positives are removed using four filters. Reads are removed on the basis of their break point score; read-through fusions are discarded; chimera pseudo-reference are created and fusion without reads aligned to the pseudo-reference are removed; PCR artifact are also removed.

*FusionFinder*\[[@B11]\] divides reads into shorter elements and it detects chimeras aligning these fragments annotated genomic reference. The main differences with respect to FusionMap are related to alignment and filter implementation. Bowtie \[[@B22]\] is used to align fragments with respect to the coding reference transcriptome. Exons tagged as fusion elements go through some filtering steps to refine the results: (i) seeds mapping on the same gene are removed; (ii) pairs of reads mapping on the same chromosome but on opposite strands are discarded; (iii) pairs of reads mapped on genomic coordinates not associated to annotated genes are removed; and (iv) artifacts caused by sequence similarity are also discarded.

*deFuse*\[[@B10]\] uses reads pairs showing discordant alignments to detect putative chimeras essentially scoring putative fusions on the basis of fusion junction coverage and considering that shift between overlapping spanning reads must be consistent with the fragment length.

For each putative fusion, chimera boundaries are used to identify encompassing reads and to define fusion boundary at the nucleotide level. Paired-end reads aligning at a length that does not match with the expected distribution of sequenced fragments distance are discarded.

*FusionHunter*\[[@B12]\] aligns paired-end reads against a reference genome using Bowtie. The mapped reads are used to identify the fusion candidates, which are aggregated to generate a pseudo reference to detect junction-spanning reads. Unmapped reads are fragmented and aligned on the pseudo-reference. If one fragment is correctly aligned, the nearest canonical splicing junction is searched and the other part of the original read is aligned to this region. Chimeras made of two genes sharing significant homology are removed. Chimeras lacking at least two different paired-end reads supporting the fusion boundary are discarded. Furthermore reads mapping on the break point with less than 6 bp are removed as well as PCR artifacts and read-through events.

*TopHat-Fusion*\[[@B16]\] detects all reads mapping entirely within exons using Bowtie, and it creates a set of partial exons from these alignments. Pseudo-genes structures are then created, while unmapped reads are split into shorter elements and mapped on the genome. Chimeras are detected if reads fragments map in a consistent way with fusions (using TopHat \[[@B18]\] with relaxed parameters). Filtering is subsequently applied to eliminate (i) chimeras associated to multi-copy genes or repetitive sequences; (ii) reads mapping with less than 13 bp on either side of fusion; and read-through events.

TopHat-Fusion also keep track of contradicting reads, i.e. the reads mapping both on a single part of fusion and on fusion boundary.

Data analysis
-------------

FusionHunter, FusionMap, FusionFinder, MapSplice, deFuse and TopHat-fusion were downloaded from the repository indicated in their papers and installed in adherence with the requirements indicated in their manual. All software tools were run with their default configuration. The analyses were performed on a 48 cores AMD server with 512 Gb RAM and 9 Tb HD, running linux SUSE Enterprise 11. Statistics and data parsing were executed using R scripting, taking advantage of the gplots-contributed R package <http://cran.r-project.org/web/packages/gplots/> and Bioconductor \[[@B19]\] packages, i.e. Biostrings, org.Hs.eg.db, GenomicRanges and oneChannelGUI \[[@B20]\].

Negative dataset
----------------

The negative dataset was generated using BEERS \[[@B17]\]<http://www.cbil.upenn.edu/BEERS/>, consisting of 70 million 100 paired-end reads (parameters: -readlength 100 -tlen 5 -tpercent 0.1). Since BEERS does not simulate Illumina quality scores, we attached to the 70 million reads the quality scores derived from 100 bp paired-end reads experiments run in our laboratory, to generate lib100_1 and lib100_2 fastq files. In addition from the 100 paired-end reads we generated a set of 2 × 75 nts (lib75_1 and lib75_2) and 2 × 50 nts paired-end reads (lib50_1 and lib50_2), removing 25 or 50 nts at the beginning of each read in the lib100_1 and lib100_2 fastq files, respectively. Negative datasets are available from the authors upon request.

Positive dataset
----------------

FusionMap <http://www.omicsoft.com/fusionmap/#Home> developers provide a synthetic dataset of simulated paired-end RNA-Seq reads (\~60,000 pairs of reads, 75 nt, fragment size = 158 bp). 50 fusions are represented, with a number of supporting pairs ranging from 9 to 8852. The sensitivity of each tool was calculated by dividing the number of chimeras detected by each tool with respect to the total number of chimeras in the positive dataset. The \"false positive\" behavior is instead reported directly as the number of chimeras detected that do not match any of the positive 50 chimeras.

Fusion genes detected in the 75 bp Body map dataset
---------------------------------------------------

Frenkel-Morgenstern\'s paper \[[@B7]\] provided, as additional information, the list of chimeras detectable in the Body Map dataset (75 bp single-end reads) and the tissue in which they were detected. Furthermore, the paper also provided the fasta files for all the analyzed 7,424 putative human chimeric RNAs. Using R <http://cran.r-project.org/> script we extracted the subset of 172 fusion events detected by Frenkel-Morgenstern in the Body Map 2.0. Each of the Frenkel-Morgenstern\'s 172 chimeras was manually blasted <http://blast.ncbi.nlm.nih.gov/Blast.cgi> against the human reference genome and we considered as a putative chimera only those characterized by a unique mapping on two different genomic locations. Moreover, we discarded all fusion events characterized by: i) having part of the sequence mapping on multiple genomic locations, ii) having the sequence mapping on the same genomic location, iii) having sequences mapping on more than two different chromosomal locations. Out of this filtering 22 fusion genes were left as putative chimeras (Table [3](#T3){ref-type="table"}).

Body Map 2.0
------------

Illumina <http://www.illumina.com> has sequenced mRNAs derived from 16 normal tissues (Body Map 2.0: Adrenal gland, Adipose tissue, Brain, Breast, Colon, Heart, Kidney, Liver, Lung, Lymph Node, Ovary, Prostate, Skeletal Muscle, Testis, Thyroid, white Blood cells). These data are public available on the GEO database (GSE30611). Approximately 80 million reads for each tissue were provided as 75 bp single-ends reads (SE) or 50 nts paired-end reads (PE) datasets. SE and PE refer to the sequencing of one and both ends of a DNA fragment, respectively. The libraries used for sequencing were derived from poly-A selected mRNAs and generated by random priming. In case of PE, the average size of the sequenced fragment was approximately 300 bp. These datasets, due to the high number of reads provided, represent an ideal instrument for the identification of chimeras associated with normal tissue and to investigate chimeras tissue specificity \[[@B7]\].
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Supplementary Material
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###### Additional file 1

**Chimeras detection in the negative datasets**. The number of reads distribution associated to false positive chimeras is shown for five fusion finders: THF1,2) TopHat-fusion with two different thresholds for the number of reads, FM1,2) FusionMap with two different thresholds for the number of reads, FF1,2) FusionFinder with two different thresholds for the number of reads, DF1,2) deFuse with two different thresholds for the number of reads, MS1,2) MapSplice with two different thresholds for the number of reads. FusionHunter is not shown since it does not detect false positive chimeras.
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